Literature DB >> 6479679

Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.

J J Rodzynek, D Urbain, P Leautaud, P Wettendorff, A Delcourt.   

Abstract

In this prospective study, antithrombin III, plasminogen and alpha 2 antiplasmin which are synthetised by the liver were measured and compared with the Normotest, Thrombotest and fibrinogen concentrations in 92 consecutive jaundiced patients. Antithrombin III appeared to be the most discriminant coagulation test in differentiating hepatocellular from cholestatic jaundice. A high correlation was observed between antithrombin III, plasminogen and alpha 2 antiplasmin values suggesting that the liver synthesis of these parameters was closely linked. The prognostic significance of the blood coagulation tests in patients with jaundice has been studied. In parenchymatous liver disease, antithrombin III, plasminogen and alpha 2 antiplasmin were superior to the Normotest, Thrombotest and fibrinogen concentrations in predicting the prognosis of the patients at the time of admission. In cholestatic jaundice, however, none of the blood coagulation tests studied had a prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6479679      PMCID: PMC1432549          DOI: 10.1136/gut.25.10.1050

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  Use of Normotest and Thrombotest, coagulation tests in hepatocellular disease.

Authors:  P Hillenbrand; S Sherlock
Journal:  Scand J Gastroenterol Suppl       Date:  1973

2.  Value of Normotest and antithrombin 3 in the assessment of liver function.

Authors:  L Mannucci; N Dioguardi; E Del Ninno; P M Mannucci
Journal:  Scand J Gastroenterol Suppl       Date:  1973

3.  Behaviour of antithrombin 3 in liver disease.

Authors:  F Duckert
Journal:  Scand J Gastroenterol Suppl       Date:  1973

4.  Antithrombin III in rat hepatocytes.

Authors:  M Léon; M Aiach; J Y Guennec; J Jarnet; R Girot; J N Fiessinger; F Jaubert
Journal:  Thromb Res       Date:  1982-10-01       Impact factor: 3.944

5.  Low antithrombin III in acute hepatic failure at term.

Authors:  J Mosvold; U Abildgaard; H Jenssen; R Andersen
Journal:  Scand J Haematol       Date:  1982-07

6.  Synthesis of alpha 2-antiplasmin by rat liver cells.

Authors:  H Högstorp; T Saldeen
Journal:  Thromb Res       Date:  1982-10-01       Impact factor: 3.944

7.  Metabolism of fibrinogen in cirrhosis of the liver.

Authors:  G N Tytgat; D Collen; M Verstraete
Journal:  J Clin Invest       Date:  1971-08       Impact factor: 14.808

8.  Fibrinolysis in cholestatic jaundice.

Authors:  A Jedrychowski; P Hillenbrand; A B Ajdukiewicz; S P Parbhoo; S Sherlock
Journal:  Br Med J       Date:  1973-03-17

9.  Improvement of some blood coagulation factors in cirrhotic patients treated with low doses of heparin.

Authors:  C Cordova; A Musca; F Violi; C Alessandri; E Vezza
Journal:  Scand J Haematol       Date:  1982-09

10.  Antithrombin III versus prothrombin in liver cirrhosis.

Authors:  M H Aurousseau; J L d'Angeli; F Josso
Journal:  Haemostasis       Date:  1981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.